MedTrace Logo

Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine

NCT07743008 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-08-03

No results posted yet for this study

Summary

This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial.

The study will include healthy adults between the ages of 18 and 65. Participants will be randomly assigned to receive either the Hia vaccine or a placebo.

The main goals of the study are to determine safety and measure immune response as it relates to protection against Hia.

Conditions

  • Haemophilus Influenzae
  • Haemophilus Influenzae Type a

Interventions

BIOLOGICAL

Haemophilus influenzae serotype a vaccine candidate

The Hia vaccine will be administered according to the Investigator Brochure.

OTHER

Saline (as a placebo)

Normal saline will be administered as a placebo as per the product monograph.

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • Dalhousie University

    collaborator OTHER

  • Canadian Center for Vaccinology

    collaborator OTHER

  • Canadian Immunization Research Network

    collaborator NETWORK

  • InventVacc Biologicals Inc.

    lead INDUSTRY

Principal Investigators

  • Joanne M Langley, MD · CIRN, Canadian Center for Vaccinology, Dalhousie University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-29
Primary Completion
2027-02-03
Completion
2027-02-03

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743008 on ClinicalTrials.gov